Will Mounjaro reduce belly fat — and does it target it specifically?

The myth: Mounjaro melts belly fat while leaving the rest of your body unchanged

This is probably the most persistent misconception about tirzepatide, and it is worth addressing head-on. No medicine approved in the UK targets a specific region of body fat. What Mounjaro does is produce substantial, consistent total weight loss, and because visceral fat (the deep abdominal fat that wraps around organs) is metabolically active, it tends to respond proportionately well to that overall loss. The SURMOUNT-1 trial, published in the New England Journal of Medicine, measured waist circumference reductions of around 14–19 cm across dose groups over 72 weeks. That is a clinically meaningful change in abdominal girth. But it came as a consequence of systemic weight loss, not because the medicine sought out belly fat specifically. Setting that expectation correctly matters, people who understand the mechanism tend to stick with treatment more successfully.

The biology behind this is worth a moment of attention. Visceral fat is more metabolically responsive than subcutaneous fat (the pinchable fat under the skin) because it has higher rates of lipid turnover and is sensitive to hormonal signals, including the GIP and GLP-1 pathways that tirzepatide activates. So while you cannot instruct your body to prioritise the abdomen, the evidence suggests the abdomen does often shift early and substantially, and if you want to understand whether Mounjaro gets rid of belly fat and what the research actually shows, we cover that question in detail. A fuller picture of the mechanism is on our page on whether tirzepatide burns belly fat.

What tirzepatide is actually doing when you lose fat around the middle

Mounjaro acts on two gut-hormone receptors simultaneously: GIP and GLP-1. This dual action reduces appetite, slows how quickly the stomach empties, and influences how the body uses and stores energy. Over weeks and months, most people eat less without feeling deprived, and the calorie deficit this creates leads to fat loss across the body. The NHS overview of tirzepatide explains this mechanism clearly for patients.

Treatment starts at a low 2.5 mg dose, which exists to let your system adjust gradually. From there, the prescriber titrates upward in roughly four-week steps toward a maintenance dose. The highest licensed UK strength is 15 mg. SURMOUNT-1 participants receiving 15 mg lost an average of around 21% of their body weight over 72 weeks, equivalent to roughly 23 kg for an 110 kg person. A proportion of that will always come from the abdomen, though the exact split varies between individuals.

One practical note: the treatment works alongside, not instead of, lifestyle changes. Participants in every tirzepatide trial followed a reduced-calorie diet and increased their physical activity. People who add resistance training while on treatment tend to preserve more lean muscle as fat is lost, which can improve how abdominal changes look and feel. Our prescribers discuss this as part of every consultation.

Who the evidence applies to, and what it cannot guarantee for you individually

The trial participants who saw those waist-circumference reductions were adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. These are the licensed criteria; a BMI figure alone does not determine whether Mounjaro is suitable, a prescriber looks at the whole picture, including your health history and any medicines you already take.

Individual variation is real. Two people can follow the same treatment plan and lose different proportions of abdominal versus total fat. Genetics, starting body composition and how closely lifestyle advice is followed all play a part. What the evidence can say is that, at a population level, meaningful reductions in abdominal fat are a consistent feature of tirzepatide treatment. What it cannot say is exactly how much belly fat you personally will lose, or how quickly.

If you are thinking about treatment costs, our Mounjaro price comparison guide for the UK sets out what private pricing typically looks like and what a legitimate quoted price should include. Pricing is one factor; clinical suitability is the starting point.

What happens in practice (and when to talk to a prescriber

Once a prescriber approves treatment, the pen arrives by DPD the next working day in plain, unbranded packaging) the same cardboard box most people walk past without a second glance. From there, the weekly routine is straightforward: one injection, rotated between the abdomen, thigh or upper arm.

Changes to abdominal fat are rarely visible in the first two to four weeks. The early weeks are largely about tolerability. Nausea, loose stools and reduced appetite are common at the start and usually settle as your body adjusts, the NHS patient information covers what to expect in detail. Most people notice clothes fitting differently around the waist before they see a big change on the scales, which is consistent with visceral fat responding early.

Mounjaro is a prescription-only medicine. A clinician needs to assess whether it is right for you before treatment begins. At nume, a GPhC-registered prescriber personally reviews every consultation, the same day you submit it. If you want to explore whether you might be eligible, speaking to our prescribers is the place to start. There is no obligation and no fee for the consultation itself. You can also read more about how Mounjaro affects belly fat and practical approaches to losing belly fat on Mounjaro if you want to go deeper on either angle before deciding.